Exelixis | EXEL - Market Capitalization


Exelixis reported $15B in Market Capitalization this June of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.8B 724M Mar/2026
Agios Pharmaceuticals USD 2.01B 423M Mar/2026
Akebia Therapeutics USD 427M 297M Dec/2025
Amgen USD 189.89B 13.64B Mar/2026
AstraZeneca USD 301.25B 13.1B Mar/2026
Bayer EUR 38.69B 2.33B Mar/2026
BioMarin Pharmaceutical USD 10.86B 553M Mar/2026
Bristol-Myers Squibb USD 123.83B 14.02B Mar/2026
Cytokinetics USD 8.19B 420M Mar/2026
Eisai JPY 1.42T 110.62B Mar/2026
Eli Lilly USD 869.02B 146.97B Mar/2026
Esperion Therapeutics USD 885M 351M Dec/2025
Exelixis USD 10.89B 857M Mar/2026
Genmab DKK 20.48B 1.02B Dec/2025
Incyte USD 18.73B 660M Mar/2026
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
Merck USD 297.1B 35.84B Mar/2026
Moderna USD 20.15B 8.53B Mar/2026
Nektar Therapeutics USD 11.91B 11.05B Jun/2026
Neurocrine Biosciences USD 13.25B 890M Mar/2026
Novartis USD 307.76B 15.54B Mar/2026
Pfizer USD 153.81B 12.24B Mar/2026
Takeda JPY 9.01T 1.37T Mar/2026
Ultragenyx Pharmaceutical USD 2.06B 159M Mar/2026
Xencor USD 893M 200M Mar/2026